Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses: 2014-2025

Historic Operating Expenses for Viking Therapeutics (VKTX) over the last 12 years, with Sep 2025 value amounting to $98.6 million.

  • Viking Therapeutics' Operating Expenses rose 169.62% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 105.15%. This contributed to the annual value of $150.9 million for FY2024, which is 49.68% up from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Operating Expenses is $98.6 million, which was up 32.17% from $74.6 million recorded in Q2 2025.
  • In the past 5 years, Viking Therapeutics' Operating Expenses ranged from a high of $98.6 million in Q3 2025 and a low of $12.5 million during Q4 2021.
  • Its 3-year average for Operating Expenses is $43.7 million, with a median of $34.1 million in 2024.
  • Data for Viking Therapeutics' Operating Expenses shows a peak YoY soared of 169.62% (in 2025) over the last 5 years.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Operating Expenses stood at $12.5 million in 2021, then surged by 62.13% to $20.3 million in 2022, then spiked by 44.38% to $29.3 million in 2023, then surged by 57.89% to $46.2 million in 2024, then spiked by 169.62% to $98.6 million in 2025.
  • Its Operating Expenses was $98.6 million in Q3 2025, compared to $74.6 million in Q2 2025 and $55.5 million in Q1 2025.